RenaSci offers all mandatory abuse and dependence testing procedures for regulatory approval of CNS-active drugs to GLP. 

We employ innovative techniques to test centrally-acting drugs including ex vivo binding, behavioural models and intracerebral microdialysis.

We have established a range of animal models for evaluating the potential of new drugs to treat obesity and NASH. 

Our animal models of diabetes can also be used to study the effects of drugs on diabetic complications including nephropathy and neuropathy.